Course: Incidence of SARS-CoV-2 Infection in Health Care Workers After a Single Dose of mRNA-1273 Vaccine
CME Credits: 1.00
Released: 2021-06-16
A 2021 randomized clinical trial demonstrated remarkably high efficacy of mRNA-1273 vaccine in reducing symptomatic SARS-CoV-2 infection after 2 doses administered 28 days apart; however, low numbers of infection during the first 2 weeks following dose 1 prevented full assessment of early vaccine efficacy. VA Boston Healthcare System (VABHS) began vaccinating health care workers (HCWs) during an early winter surge in SARS-CoV-2 infections in Massachusetts. A concomitant large increase in SARS-CoV-2 infections in our workforce provided an opportunity to evaluate the association between receipt of dose 1 of mRNA-1273 vaccine and SARS-CoV-2 infection.
Educational Objective
To identify the key insights or developments described in this article
View Full Course